Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia
- PMID: 32857324
- DOI: 10.1007/s13402-020-00551-3
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia
Abstract
Purpose: Acute lymphoblastic leukemia (ALL) is an aggressive hematological cancer with limited therapeutic options for adult patients. Aurora kinases have drawn attention as potential targets in hematological neoplasms due to their high expression and biological functions. Aurora kinase A (AURKA) and AURKB are essential for a successful mitosis, acting in spindle mitotic organization and cytokinesis. Reversine is a synthetic purine analog that acts as a multi-kinase inhibitor with anti-neoplastic activity by targeting AURKA and AURKB.
Methods: ALL patient gene expression data were retrieved from the Amazonia!
Database: For functional assays, Jurkat (T-ALL) and Namalwa (B-ALL) cells were exposed to increasing concentrations of reversine and submitted to various cellular and molecular assays.
Results: We found that AURKB expression was higher in ALL patient samples compared to normal lymphocytes (p < 0.0001). The ALL cell lines tested displayed aberrant AURKA and AURKB expression. In Jurkat and Namalwa cells, reversine reduced cell viability in a dose- and time-dependent manner (p < 0.05). Reversine also significantly reduced the viability of primary ALL cells. Reversine induced apoptosis and autophagy, and reduced cell proliferation in both cell lines (p < 0.05). Mitotic catastrophe markers, including cell cycle arrest at G2/M, increased cell size and DNA damage, were observed upon reversine exposure. Short- and long-term treatment with reversine inhibited autonomous clonogenicity (p < 0.05). At the molecular level, reversine reduced AURKB activity, induced SQSTM1/p62 consumption, and increased LC3BII and γ-H2AX levels. In Namalwa cells, reversine modulated 25 out of 84 autophagy-related genes, including BCL2, BAD, ULK1, ATG10, IRGM and MAP1LC3B, which indicates that reversine acts by initiating and sustaining autophagy signals in ALL cells.
Conclusions: From our data we conclude that reversine reduces the viability of ALL cells by triggering multiple cell death mechanisms, including apoptosis, mitotic catastrophe, and autophagy. Our findings highlight reversine as a potential anticancer agent for ALL.
Keywords: Acute lymphoblastic leukemia; Aurora kinases; Cell death; Reversine.
Similar articles
-
Targeting glioma cells by antineoplastic activity of reversine.Oncol Lett. 2021 Aug;22(2):610. doi: 10.3892/ol.2021.12871. Epub 2021 Jun 15. Oncol Lett. 2021. PMID: 34188712 Free PMC article.
-
Reversine triggers mitotic catastrophe and apoptosis in K562 cells.Leuk Res. 2016 Sep;48:26-31. doi: 10.1016/j.leukres.2016.06.011. Epub 2016 Jul 1. Leuk Res. 2016. PMID: 27447890
-
Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms.Sci Rep. 2019 Jul 9;9(1):9895. doi: 10.1038/s41598-019-46163-2. Sci Rep. 2019. PMID: 31289316 Free PMC article.
-
Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis.Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108376. doi: 10.1016/j.mrrev.2021.108376. Epub 2021 Apr 24. Mutat Res Rev Mutat Res. 2021. PMID: 34083040 Review.
-
Reversine: A Synthetic Purine with a Dual Activity as a Cell Dedifferentiating Agent and a Selective Anticancer Drug.Curr Med Chem. 2020;27(21):3448-3462. doi: 10.2174/0929867326666190103120725. Curr Med Chem. 2020. PMID: 30605049 Review.
Cited by
-
Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax.Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):124-127. doi: 10.1016/j.htct.2021.01.004. Epub 2021 Mar 13. Hematol Transfus Cell Ther. 2022. PMID: 33753045 Free PMC article. No abstract available.
-
Targeting glioma cells by antineoplastic activity of reversine.Oncol Lett. 2021 Aug;22(2):610. doi: 10.3892/ol.2021.12871. Epub 2021 Jun 15. Oncol Lett. 2021. PMID: 34188712 Free PMC article.
-
Development of 2-Aminoadenine-Based Proteolysis-Targeting Chimeras (PROTACs) as Novel Potent Degraders of Monopolar Spindle 1 and Aurora Kinases.ACS Pharmacol Transl Sci. 2024 Oct 19;7(11):3488-3501. doi: 10.1021/acsptsci.4c00405. eCollection 2024 Nov 8. ACS Pharmacol Transl Sci. 2024. PMID: 39539259
References
-
- S.P. Hunger, C.G. Mullighan, Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541–1552 (2015) - PubMed
-
- J.R. Bischoff, L. Anderson, Y. Zhu, K. Mossie, L. Ng, B. Souza, B. Schryver, P. Flanagan, F. Clairvoyant, C. Ginther, C.S. Chan, M. Novotny, D.J. Slamon, G.D. Plowman, A homologue of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17, 3052–3065 (1998) - PubMed - PMC
-
- D. Li, J. Zhu, P.F. Firozi, J.L. Abbruzzese, D.B. Evans, K. Cleary, H. Friess, S. Sen, Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin. Cancer Res. 9, 991–997 (2003) - PubMed
-
- R. Reiter, P. Gais, U. Jutting, M.K. Steuer-Vogt, A. Pickhard, K. Bink, S. Rauser, S. Lassmann, H. Hofler, M. Werner, A. Walch, Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin. Cancer Res. 12, 5136–5141 (2006) - PubMed
MeSH terms
Substances
Grants and funding
- 2017/24993-0/Fundação de Amparo à Pesquisa do Estado de São Paulo
- 2018/19372-9/Fundação de Amparo à Pesquisa do Estado de São Paulo
- 2015/17177-6/Fundação de Amparo à Pesquisa do Estado de São Paulo
- 402587/2016-2/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- #/Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous